Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: A comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936 [1]

Diabetologia

Volumn 50, Issue 5, 2007, Pages 1109-1110

  Raccah, D ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DRUG FATALITY; HUMAN; LETTER; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; HUMANS; METFORMIN; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 34147155841     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-007-0630-3     Document Type: Letter

References (11)

1. Tayek JA (2006) Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.
2. Diabetologia 49:2807-2808
3. Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936
4. Salsburg DS (1971) The UGDP study. JAMA 218:1704-1705
5. Simpson SH, Mujamdar SR, Tsuyuki RT, Eurich DT, Johnson JA (2006) Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174:169-174
6. Johnson JA, Mujamdar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244-2248
7. Johnson JA, Simpson SH, Toth EL, Mujamdar SR (2005) Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 22:497-502
8. Olsson J, Lindberg G, Gottsater M et al (2000) Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43:558-560
9. United Kingdom Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865
10. Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
11. Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711-1721